3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
6
Gastrointestinal
6
Endocrine
6
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Solid Tumor
87
Advanced Solid Tumor
80
Advanced Solid Tumors
70
Mesothelioma, Malignant
41
Solid Tumor, Adult
29
Mesothelioma
28
Solid Tumors
24
Unspecified Adult Solid Tumor, Protocol Specific
21
Retinoblastoma
19
Carcinoma, Non-Small-Cell Lung
11
Stomach Neoplasms
9
Ovarian Neoplasms
8
Advanced Malignant Solid Tumors
7
Advanced Malignant Solid Tumor
7
Pancreatic Neoplasms
6
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Lung Neoplasms
5
Locally Advanced or Metastatic Solid Tumors
5
Esophageal Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Pleural Effusion, Malignant
4
Malignant Solid Tumors
4
Lymphoma
4
Carcinoma, Hepatocellular
4
Unspecified Childhood Solid Tumor, Protocol Specific
3
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastro-enteropancreatic neuroendocrine tumor
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled